Fan Hai-Na, Zhao Zhi-Min, Huang Kai, Wang Xiao-Ning, Dai Yun-Kai, Liu Cheng-Hai
Institute of Liver Diseases, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Shuguang Hospital, Shanghai, China.
Front Pharmacol. 2023 Dec 21;14:1329266. doi: 10.3389/fphar.2023.1329266. eCollection 2023.
The serum metabolites changes in patients with hepatitis B virus (HBV)-related cirrhosis as progression. Peroxisome proliferator-activated receptor gamma (PPARγ) is closely related to lipid metabolism in cirrhotic liver. However, the relationship between fatty acids and the expression of hepatic PPARγ during cirrhosis regression remains unknown. In this study, we explored the serum metabolic characteristics and expression of PPARγ in patients with histological response to treatment with entecavir. Sixty patients with HBV-related cirrhosis were selected as the training cohort with thirty patients each in the regression (R) group and non-regression (NR) group based on their pathological changes after 48-week treatment with entecavir. Another 72 patients with HBV-related cirrhosis and treated with entecavir were collected as the validation cohort. All of the serum samples were tested using ultra-performance liquid chromatography coupled to tandem mass spectrometry. Data were processed through principal component analysis and orthogonal partial least square discriminant analysis. Hepatic PPARγ expression was observed using immunohistochemistry. The relationship between serum fatty acids and PPARγ was calculated using Pearson's or Spearman's correlation analysis. A total of 189 metabolites were identified and 13 differential metabolites were screened. Compared to the non-regression group, the serum level of fatty acids was higher in the R group. At baseline, the expression of PPARγ in hepatic stellate cells was positively correlated with adrenic acid ( = 0.451, = 0.046). The expression of PPARγ in both groups increased after treatment, and the expression of PPARγ in the R group was restored in HSCs much more than that in the NR group ( = 0.042). The adrenic acid and arachidonic acid (AA) in the R group also upgraded more than the NR group after treatment ( = 0.037 and 0.014). Baseline serum differential metabolites, especially fatty acids, were identified in patients with HBV-related cirrhosis patients who achieved cirrhosis regression. Upregulation of adrenic acid and arachidonic acid in serum and re-expression of PPARγ in HSCs may play a crucial role in liver fibrosis improvement.
乙型肝炎病毒(HBV)相关肝硬化患者血清代谢物随病情进展的变化。过氧化物酶体增殖物激活受体γ(PPARγ)与肝硬化肝脏中的脂质代谢密切相关。然而,在肝硬化消退过程中脂肪酸与肝脏PPARγ表达之间的关系仍不清楚。在本研究中,我们探讨了恩替卡韦治疗组织学反应患者的血清代谢特征及PPARγ表达。选取60例HBV相关肝硬化患者作为训练队列,根据恩替卡韦治疗48周后的病理变化,将其分为消退(R)组和未消退(NR)组,每组30例。另收集72例接受恩替卡韦治疗的HBV相关肝硬化患者作为验证队列。所有血清样本均采用超高效液相色谱-串联质谱法检测。数据通过主成分分析和正交偏最小二乘判别分析进行处理。采用免疫组织化学法观察肝脏PPARγ表达。采用Pearson或Spearman相关分析计算血清脂肪酸与PPARγ之间的关系。共鉴定出189种代谢物,筛选出13种差异代谢物。与未消退组相比,R组血清脂肪酸水平更高。基线时,肝星状细胞中PPARγ的表达与肾上腺酸呈正相关(r = 0.451,P = 0.046)。两组治疗后PPARγ表达均升高,且R组肝星状细胞中PPARγ的表达恢复程度远高于NR组(P = 0.042)。治疗后R组的肾上腺酸和花生四烯酸(AA)也比NR组升高更多(P = 0.037和0.014)。在实现肝硬化消退的HBV相关肝硬化患者中鉴定出基线血清差异代谢物,尤其是脂肪酸。血清中肾上腺酸和花生四烯酸的上调以及肝星状细胞中PPARγ的重新表达可能在肝纤维化改善中起关键作用。